
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
ICON, a provider of drug development services, announced the release of ADDPLAN® neo, providing a technology platform for design, simulation, and analysis of adaptive clinical trials. The new release combines three modules, ADDPLAN® BASE, ADDPLAN® MC, and ADDPLAN® DF to become integrated under one robust framework.
Read the full release






